Revolution Medicines Inc (RVMD)
Revolution Medicines Inc (RVMD) carries a ŷRobot AI score of 78 out of 100. The model's fair value estimate is $215.74, 14.7% above the last close of $188.12. The chart signal reads Bearish.
| Metric | RVMD |
|---|---|
| AI score | 78 / 100 |
| Chart signal | Bearish |
| Fair value estimate | $215.74 |
| Upside to fair value | 14.7% |
| Previous close | $188.12 |
| P/E | -23.24 |
| Price / sales | 59,473.91 |
| Market cap | $42.84B |
| EPS | -8.86 |
| Revenue growth | -100.3% |
| 1-year price change | 40.1% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, Merck & Company Inc, UnitedHealth Group Incorporated, Novartis AG ADR.
Questions about RVMD
Is RVMD overvalued or undervalued right now?
As of Oct 8, 2026, ŷRobot's fair-value model estimates Revolution Medicines Inc (RVMD) at $215.74 against a last close of $188.12, implying 14.7% upside to the model's estimate.
Is RVMD's chart signal bullish or bearish?
The chart-signal model classifies RVMD as Neutral as of Oct 8, 2026, with a signal score of -0.01 on a -1 to 1 scale.
What is RVMD's ŷRobot AI score?
RVMD scores 78 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Oct 8, 2026.
Is RVMD stock expensive on P/E and P/S?
RVMD trades at -23.2 times earnings and 59473.9 times sales as of Oct 8, 2026.
What does RVMD's seasonal forecast show?
ŷRobot's seasonal forecast curve for RVMD reads +5.9% at 30 days, +18.5% at 90 days, and +40.1% at one year as of Oct 8, 2026. Seasonal tendencies are historical patterns, not predictions.
How fast is RVMD growing?
Revolution Medicines Inc's revenue growth is -100.3% and free-cash-flow growth is +12.9% on the latest reported figures.
RVMD chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.